Bingham Private Wealth LLC Purchases Shares of 5,019 AbbVie Inc. $ABBV

Key Points

• Bingham Private Wealth LLC purchased a new stake of 5,019 shares of AbbVie in Q4, valued at about $1.15 million, making AbbVie 0.9% of the firm's holdings and its 28th largest position.
• AbbVie beat Q4 estimates and set FY2026 guidance (EPS 14.37–14.57) and has several near‑term catalysts — notably positive Phase 2 data for Elahere (mirvetuximab) in ovarian cancer and an exclusive licensing deal with Haisco for pain assets (~$715–745M) — which helped lift analyst sentiment (price target to $249).
• Corporate insiders sold shares recently (EVP Perry Siatis: 22,381 shares; SVP David Ryan Purdue: 5,230 shares), the board declared a $1.73 quarterly dividend (3.3% yield), and institutional investors own roughly 70.23% of AbbVie stock.

Bingham Private Wealth LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,019 shares of the company's stock, valued at approximately $1,147,000. AbbVie accounts for 0.9% of Bingham Private Wealth LLC's holdings, making the stock its 28th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its stake in shares of AbbVie by 89.8% in the 4th quarter. Farther Finance Advisors LLC now owns 90,459 shares of the company's stock valued at $20,669,000 after purchasing an additional 42,801 shares in the last quarter. Tyche Wealth Partners LLC lifted its stake in shares of AbbVie by 14.5% in the 4th quarter. Tyche Wealth Partners LLC now owns 19,447 shares of the company's stock valued at $4,443,000 after purchasing an additional 2,470 shares in the last quarter. Patton Fund Management Inc. lifted its stake in shares of AbbVie by 740.6% in the 4th quarter. Patton Fund Management Inc. now owns 10,768 shares of the company's stock valued at $2,460,000 after purchasing an additional 9,487 shares in the last quarter. Cove Private Wealth LLC lifted its stake in shares of AbbVie by 12.3% in the 4th quarter. Cove Private Wealth LLC now owns 11,131 shares of the company's stock valued at $2,543,000 after purchasing an additional 1,220 shares in the last quarter. Finally, Galvin Gaustad & Stein LLC lifted its stake in shares of AbbVie by 1.1% in the 4th quarter. Galvin Gaustad & Stein LLC now owns 5,567 shares of the company's stock valued at $1,272,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data showed Elahere (mirvetuximab) demonstrated efficacy and safety in platinum‑sensitive ovarian cancer — news that strengthens AbbVie’s oncology story and could support future uptake/launch value. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive licensing deal with China’s Haisco for pain assets (deal reported up to ~$715–745M), giving AbbVie global rights outside China and expanding its pain pipeline — a near‑term catalyst for pipeline diversification and future revenue optionality. AbbVie inks $715M deal with Chinese biotech Haisco
• Positive Sentiment: An analyst price target lift to $249 signals bullish sell‑side sentiment and likely supports buying interest. AbbVie NYSE: ABBV Price Target Raised to $249.00
• Positive Sentiment: AbbV-438 myeloma Phase 1 update highlights AbbVie’s early‑stage oncology investments — an incremental positive for long‑term oncology growth, though clinical risk remains. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: Analysts and coverage pieces note neuroscience brands (Botox, Vraylar) are expected to help Q1 top‑line performance — supportive but dependent on execution and pricing dynamics. Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Coverage on AbbVie entering the weight‑loss arena notes progress but says the company remains behind leaders (e.g., Lilly) — a mixed signal on competitive positioning in metabolic/weight‑loss space. Could AbbVie Crash Lilly's Weight‑Loss Party?
• Neutral Sentiment: Marketing/aesthetics PR (Natrelle breast‑implant campaign) increases brand visibility for Allergan Aesthetics, useful for the consumer/aesthetics business but unlikely to move fundamentals materially. Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Analyst Ratings Changes

ABBV has been the topic of several research analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Cantor Fitzgerald reduced their price objective on AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 8th. UBS Group reduced their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

AbbVie Stock Up 1.9%

NYSE ABBV opened at $210.29 on Wednesday. The stock has a market cap of $371.83 billion, a PE ratio of 89.11, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a fifty-two week low of $168.54 and a fifty-two week high of $244.81. The business has a 50 day moving average price of $219.66 and a two-hundred day moving average price of $223.88.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.